Vicki Lin, MD
Ophthalmology · Fountain Valley, CANPI 1326146937
Payments from drug & device makers
Across 319 payments — averaging $27.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$1K
- Sun Pharmaceutical Industries Inc.$1K
- Oyster Point Pharma, Inc.$745
- Aerie Pharmaceuticals, Inc.$528
- Bausch & Lomb Americas Inc.$342
- plus $3K from 20 others
What the payments were for
- Speaking & faculty fees$90010%
- Food & beverage$7,86889%
- Education$250%
- Gifts$641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 34 | $2,133 |
| AbbVie(2 entities) | 74 | $1,433 |
| Sun Pharmaceutical Industries Inc. | 49 | $1,065 |
| Oyster Point Pharma, Inc. | 20 | $745 |
| Aerie Pharmaceuticals, Inc. | 29 | $528 |
| Bausch & Lomb Americas Inc. | 12 | $342 |
| Dompe US, Inc. | 11 | $336 |
| Shire North American Group Inc | 14 | $280 |
| ANI Pharmaceuticals, Inc. | 13 | $267 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $229 |
| Sight Sciences, Inc. | 5 | $197 |
| Ivantis, Inc | 2 | $174 |
| Novartis | 9 | $169 |
| Mallinckrodt Hospital Products Inc. | 8 | $157 |
| Tarsus Pharmaceuticals, Inc. | 5 | $147 |
| Thea Pharma Inc. | 6 | $137 |
| NEW World Medical,inc. | 3 | $101 |
| Amgen | 4 | $83 |
| Harrow Eye, LLC | 3 | $82 |
| Eyevance Pharmaceuticals LLC | 4 | $72 |
| Rayner Intraocular Lenses Limited | 2 | $54 |
| Alcon Research LLC | 1 | $35 |
| Rxsight Inc | 1 | $27 |
| Astellas Pharma US Inc | 1 | $23 |
| Kala Pharmaceuticals, Inc. | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYRVAYA$293
- XEN GLAUCOMA TREATMENT SYSTEM$145
- Clareon PanOptix Pro$145
- Precision 1$145
- Hydrus$136
- Rhopressa$128
- Rocklatan$128
- ILUX$128
- PURIFIED CORTROPHIN GEL$125
- OMNI(R) SURGICAL SYSTEM (US)$125
- VUITY$115
- enVista MX60 IOL$111
- Oxervate$101
How this compares
$8,857 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $338,573 |
| RestasisCyclosporine | 174 | $209,340 |
| MieboPerfluorohexyloctane/Pf | 118 | $92,055 |
| XiidraLifitegrast | 47 | $73,838 |
| CequaCyclosporine | 68 | $69,067 |
| LumiganBimatoprost | 92 | $56,226 |
| Cyclosporine | 62 | $36,236 |
| RocklatanNetarsudil Mesylat/Latanoprost | 97 | $34,046 |
| TyrvayaVarenicline Tartrate | 43 | $32,770 |
| VyzultaLatanoprostene Bunod | 98 | $27,245 |
| CombiganBrimonidine Tartrate/Timolol | 85 | $22,062 |
| Alphagan PBrimonidine Tartrate | 74 | $18,506 |
| ZioptanTafluprost/Pf | 47 | $16,325 |
| VevyeCyclosporine | 16 | $14,981 |
| ProlensaBromfenac Sodium | 36 | $12,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $336 | $338,57312 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,433 | $306,134425 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $342 | $193,138263 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,065 | $69,06768 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $528 | $34,04697 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $745 | $32,77043 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $229 | $17,37757 claims |
| Harrow Eye, LLCVevye | $82 | $14,98116 claims |
| Thea Pharma Inc.Iyuzeh | $137 | $9,87230 claims |
| AlconSimbrinza | $2,133 | $6,12623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Fountain Valley
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.